<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02409381</url>
  </required_header>
  <id_info>
    <org_study_id>ACH-MTR-04(02/13)</org_study_id>
    <nct_id>NCT02409381</nct_id>
  </id_info>
  <brief_title>Extract of Curcuma Longa Complexed With Phosphatidilcholine(Motore®)in the Treatment of Adults With Knee Osteoarthritis</brief_title>
  <official_title>Clinical Trial, Multicenter, Phase IV, Open, Randomized, Parallel, Controlled, Non-inferiority, to Evaluate the Efficacy and Safety of Motore® Compared to Alivium® in the Treatment of Adults With Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ache Laboratorios Farmaceuticos S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ache Laboratorios Farmaceuticos S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, phase IV, open, randomized, parallel, controlled, in which 288 (two
      hundred and eighty-eight) participants of both sexes, aged between 40 and 75 years will be
      randomly allocated to one of two treatment groups , and treatment group 01 will be the dried
      extract of Curcuma longa complexed with phosphatidylcholine (Motore®), and treatment group 02
      will ibuprofen (Alivium®).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluate the efficacy and safety of Dry Extract of Curcuma Longa complexed with
      phosphatidilcholine (Motore®) Compared to Ibuprofen (Alivium® ) in the treatment of adults
      with knee osteoarthritis. The study population will consist in participants of both sexes,
      aged between 40 and 80 years old with a clinical diagnosis of knee osteoarthritis
      (tibiofemoral joint) based on clinical and radiological criteria (Grades 2 and 3 Kellgren and
      Lawrence) and who had osteoarthritis symptoms in the last six (06) months preceding the start
      of the study. They will be randomly allocated to one of two treatment groups , and treatment
      group 01 will be the dried extract of Curcuma longa complexed with phosphatidylcholine
      (Motore®), and treatment group 02 will ibuprofen (Alivium®).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in the pain domain score of the WOMAC questionnaire</measure>
    <time_frame>After 42 (forty two) days of treatment</time_frame>
    <description>The primary efficacy endpoint will be the reduction in the pain domain score of the WOMAC questionnaire after 42 (forty two) days of treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">288</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Motore</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Curcuma longa complexed with phosphatidylcholine - 250 mg (Motore®), two (02) capsules orally every twelve (12) hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alivium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ibuprofen 600 mg (Alivium®), one (01) coated tablet orally, every six (06) hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Motore</intervention_name>
    <description>250 mg</description>
    <arm_group_label>Motore</arm_group_label>
    <other_name>Group 1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alivium</intervention_name>
    <description>600 mg</description>
    <arm_group_label>Alivium</arm_group_label>
    <other_name>Group 2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants of both sexes;

          -  Age greater than or equal to 40 years and less than or equal to 75 years;

          -  Clinical diagnosis of osteoarthritis of the knee (tibiofemoral joint) based on
             clinical and radiological criteria (Grade 2 and 3 Kellgren and Lawrence) as specified
             below:

          -  Pain on movement in the affected knee on most days of the last month, with at least
             partial relief at rest;

          -  Presence of osteophytes of at least 1 mm in radiological imaging, a report issued by a
             qualified professional from the center;

          -  Symptoms of osteoarthritis in the last 06 months preceding the start of the study;

          -  Visual Analogue Scale with 40mm or greater value (considering the data obtained at the
             randomization visit);

          -  Ability to understand and consent to participate in this clinical study, manifested by
             signing the Informed Consent Form (ICF).

        Exclusion Criteria:

          -  Any finding of clinical observation (clinical and physical examination) or laboratory
             finding that is interpreted by the researcher as a medical risk to participation in
             the clinical trial;

          -  Any finding of ECG examination the investigator physician considers risk as to the
             research participant about their participation in the clinical trial;

          -  Known hypersensitivity to the components of the medications used during the study;

          -  Women in pregnancy or nursing period;

          -  in premenopausal women who do not agree to use acceptable contraceptive methods (oral
             contraceptives, injectable contraceptives, hormonal implants, barrier methods,
             abstinence, hormonal patch and tubal ligation); except surgically sterile (bilateral
             oophorectomy or hysterectomy);

          -  concomitant arthropathy that may confuse or interfere with pain assessment or
             efficacy, including: inflammatory arthropathy (rheumatoid arthritis, systemic lupus
             erythematosus, spondyloarthropathy, psoriatic arthritis, polymyalgia rheumatic), gouty
             arthritis, acute episodes of monoarthritis compatible with pseudogout, Paget's disease
             with involvement of the joint study, history of septic arthritis, avascular necrosis
             or intra-articular joint studied, Wilson's disease, hemochromatosis, alkaptonuria,
             primary osteochondromatosis fracture;

          -  Infectious Arthritis as gonococcal and syphilitic;

          -  History of significant collateral ligament injury, or anterior cruciate, or the
             meniscus of the joint study, requiring surgery or immobilization for more than three
             weeks (minor ligament injuries, six months prior to the study, are not exclusion
             criteria );

          -  History of arthroscopy of the affected knee during the six months preceding the entry
             of the research participant in the study;

          -  History of any illness that, in the opinion of the investigator, might confound the
             results of the study or research participant put on additional risk;

          -  Treatment with corticosteroids as follows:

          -  Use of corticosteroids orally or intramuscularly for one month prior to the
             randomization visit (V0);

          -  Administration of intra-articular corticosteroid, the joint study in the previous
             three months at randomization visit (V0);

          -  Administration of intra-articular corticosteroids in any joint a visit prior to
             randomization (V0) month;

          -  intra-articular injection of hyaluronic acid in the joint or congeners studied in the
             last twelve months prior to randomization visit (V0);

          -  Implementation of any other medical treatment for osteoarthritis in the
             pre-randomization visit (V0) months;

          -  Body Mass Index (BMI) equal to or greater than 35;

          -  Participant that is in use Prohibited Drug;

          -  the presence of serious psychiatric illness of any kind that prevents the proper
             performance of study-related procedures and good adherence to treatment;

          -  Participant that has some relation to the second degree of kinship or relationship
             with employees or employees of Sponsor and Research Center.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Rocha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Artroclinica de Fortaleza</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ache Laboratorios Farmaceuticos</name>
      <address>
        <city>Guarulhos</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2015</study_first_submitted>
  <study_first_submitted_qc>April 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2015</study_first_posted>
  <last_update_submitted>August 24, 2016</last_update_submitted>
  <last_update_submitted_qc>August 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

